AxoGen, Inc. (NASDAQ:AXGN) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of AxoGen, Inc. (NASDAQ:AXGN) have been given an average recommendation of “Moderate Buy” by the eleven research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $46.50.

A number of analysts have commented on AXGN shares. HC Wainwright raised their price objective on AxoGen from $39.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Wells Fargo & Company raised their price objective on shares of AxoGen from $40.00 to $48.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Raymond James Financial reissued an “outperform” rating and issued a $48.00 target price on shares of AxoGen in a research note on Wednesday, April 29th. Citigroup restated an “outperform” rating on shares of AxoGen in a research note on Wednesday, April 29th. Finally, Lake Street Capital increased their target price on AxoGen from $40.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, April 23rd.

Insider Transactions at AxoGen

In other AxoGen news, Director Kathy Johnson Weiler sold 16,344 shares of the business’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $44.09, for a total value of $720,606.96. Following the completion of the transaction, the director directly owned 16,344 shares of the company’s stock, valued at approximately $720,606.96. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John Johnson sold 11,050 shares of the stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $43.26, for a total value of $478,023.00. Following the completion of the sale, the director owned 11,050 shares of the company’s stock, valued at $478,023. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 29,041 shares of company stock valued at $1,268,792. Corporate insiders own 2.44% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. MCF Advisors LLC acquired a new position in AxoGen in the 4th quarter worth $30,000. Arax Advisory Partners boosted its position in AxoGen by 362.4% during the 4th quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 819 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of AxoGen in the fourth quarter valued at approximately $36,000. Kestra Advisory Services LLC acquired a new position in AxoGen during the fourth quarter worth $39,000. Finally, KBC Group NV acquired a new stake in AxoGen in the 1st quarter valued at $41,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Stock Performance

Shares of AXGN remained flat at $45.89 during mid-day trading on Friday. The stock had a trading volume of 2,408,544 shares, compared to its average volume of 1,539,616. The business has a 50 day moving average of $42.32 and a 200-day moving average of $36.12. The firm has a market capitalization of $2.44 billion, a price-to-earnings ratio of -71.70 and a beta of 1.09. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.10 and a quick ratio of 5.33. AxoGen has a 12 month low of $10.71 and a 12 month high of $46.95.

AxoGen (NASDAQ:AXGN) last released its earnings results on Tuesday, April 28th. The medical equipment provider reported $0.07 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.05). AxoGen had a negative net margin of 13.21% and a negative return on equity of 9.63%. The company had revenue of $61.46 million for the quarter, compared to analyst estimates of $57.85 million. Analysts expect that AxoGen will post -0.37 EPS for the current fiscal year.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.